Efficacy and Safety of Radiotherapy Combined with Pyrotinib in the Treatment of HER2-Positive Breast Cancer with Brain Metastases
Jie Huang, Wenqiang Zhu, Qiangzhi Duan, Chaomang Zhu, Xueling Shi, Hongyu Zhao, Peng Cai, Duojie Li · 2023
Read Efficacy and Safety of Radiotherapy Combined with Pyrotinib in the Treatment of HER2-Positive Breast Cancer with Brain Metastases by Jie Huang, Wenqiang Zhu, Qiangzhi Duan, Chaomang Zhu, Xueling Shi, Hongyu Zhao, Peng Cai, Duojie Li (2023) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-10661917.txt.
Description
Jie Huang and a team of co-authors compare pairing radiation with a targeted drug for breast cancer spread to the brain, in a paper dated twenty twenty-three. The cancer type carries the HER2 marker, and all patients took pyrotinib. Sixty-six also got radiation, while twenty-six took the drug alone.
The paired group answered treatment more often, at about fifty-five percent versus thirty-five. Their cancer also stayed quiet in the brain longer, twelve months against eight. A stronger split-dose radiation plan beat the standard plan on both control and survival. No grave side effects appeared in either group.
Catalog record
| CREATOR | Jie Huang, Wenqiang Zhu, Qiangzhi Duan, Chaomang Zhu, Xueling Shi, Hongyu Zhao, Peng Cai, Duojie Li |
|---|---|
| YEAR | 2023 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 34 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |